Navigation Links
Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R)
Date:3/12/2010

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements.  These statements are based on the Company's current beliefs and expectations.  These forward-looking statements include statements regarding the potential for, and timing of, filing an NDA for Contrave.  The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved.  Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: risks inherent in the continued analyses of clinical trial results, including Contrave Phase 3 trials; the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave and Empatic; reliance on third parties to assist with the development of Contrave and Empatic and the regulatory submissions related thereto; the potential for adverse safety findings relating to Contrave or Empatic; and other risks described in the Company's filings with the Securities and Exchange Commission.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  The orthopedic specialists at Midwest Orthopaedics ... orthopedic group by US News & World Report, are ... of free, public seminars to discuss partial and total ... come to see the knee physicians at Midwest Orthopaedics ... at Munster Specialty Surgery Center. The ...
(Date:9/30/2014)... 2014  Life Science Angels (LSA), a Bay ... emerging biotech, medical device, genomics, diagnostic and mobile ... Investment Group in the U.S.  LSA was recognized ... of 370 angel groups analyzed nationwide based on ... selection aptitude and brand recognition.  LSA was launched ...
(Date:9/30/2014)... 30, 2014  The Corporate Whistleblower Center is ... them at 866-714-6466 if they have well documented ... should have been sent home, as an intentional ... be substantial, as the Center would like to ... http://photos.prnewswire.com/prnh/20140929/149016 Photo - ...
Breaking Medicine Technology:"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Life Science Angels Ranked the Top Angel Investment Group in the U.S. 2Life Science Angels Ranked the Top Angel Investment Group in the U.S. 3Corporate Whistleblower Center Urges ER Doctors or Nurse Managers to Call Them if They Have Proof of a Hospital Needlessly Admitting Medicare Patients Instead of Sending Them Home 2Corporate Whistleblower Center Urges ER Doctors or Nurse Managers to Call Them if They Have Proof of a Hospital Needlessly Admitting Medicare Patients Instead of Sending Them Home 3Corporate Whistleblower Center Urges ER Doctors or Nurse Managers to Call Them if They Have Proof of a Hospital Needlessly Admitting Medicare Patients Instead of Sending Them Home 4
... BUENOS AIRES, Argentina, May 21 Today at ... entitled "New,Perspectives in Atrial Fibrillation Management" chaired by ... of London,highlighted the importance of the newly announced ... the future management of Atrial,fibrillation, the most common ...
... Significant Reduction of IBS Pain and Normalizing Motility ... ... May 20 Tioga Pharmaceuticals, Inc. today,announced the results of ... agonist, asimadoline, which demonstrated statistically significant,results in the treatment of ...
Cached Medicine Technology:ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 2Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 3Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 4
(Date:9/30/2014)... Speaking on this occasion, Dr. Srinubabu ... as a remarkable event, which brings together a unique ... research and diagnostic companies, leading universities and medical research ... to share experience, foster collaborations across industry and academia ... is a forum to explore issues of mutual concern ...
(Date:9/30/2014)... 30, 2014 Imagine living spring to ... stop respiratory symptoms quickly, they can make us drowsy ... in some cases may have side effects that compromise ... says The Mushroom Lady, Sandra Williams of Lost ... Doug Williams, shiitake mushroom growers for almost 30 years, ...
(Date:9/30/2014)... USA (PRWEB) September 30, 2014 MyMobileUni ... sector, and NGO’s who have similar shared vision to ... Lawrence Wasserman, Honorary Advisor (MMU):, ... anywhere, anytime 24/7 for all ages , ... girls, child empowerment , to promote equal ...
(Date:9/30/2014)... its partners successfully established a visual mapping of ... derived suppressor cells (MDSC). The damage and immune ... however this is a major stepping stone in ... tumor-derived factors from precursors present in hematopoietic organs ... This population of cells suppresses the activity of ...
(Date:9/30/2014)... families of patients with bowel cancer for a genetic ... and ovarian cancers, new research has found. , In ... School of Medicine and researchers from the University of ... UK-wide screening programme for a genetic condition known as ... is a caused by changes in genes which check ...
Breaking Medicine News(10 mins):Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 2Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 3Health News:Fall Allergy Season: Reishi Mushrooms Treat the Immune System and the Body Cures the Allergies. 2Health News:Fall Allergy Season: Reishi Mushrooms Treat the Immune System and the Body Cures the Allergies. 3Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 2Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 3Health News:Genetic test would help 'cut bowel cancer spread' 2Health News:Genetic test would help 'cut bowel cancer spread' 3
... By Amanda Gardner HealthDay Reporter , MONDAY, ... ubiquitous and pedestrian drugs -- aspirin -- may cut the ... has not yet spread beyond the gland, a new study ... 5,000 men with prostate cancer, 2,000 of whom were taking ...
... prostate cancer treated with a specialized type of ... fewer gastrointestinal complications compared to patients treated with ... study presented November 1, 2010, at the 52nd ... Oncology (ASTRO). , "With survivors living ...
... chemotherapy to radiation therapy for muscle invasive bladder cancer allows ... their bladders two years after treatment. This compares to 54 ... largest randomized study of its kind presented at the plenary ... the American Society for Radiation Oncology (ASTRO). , "The trial ...
... October 25, 2010 The Life Sciences Discovery Fund (LSDF) ... Corporation (NASDAQ: OMER) to discover, develop, and commercialize new ... successful generation of proceeds through partnering and the sales ... the grant would be establishment of a new non-profit ...
... By Serena Gordon HealthDay Reporter , MONDAY, Oct. ... to sleep-starved parents: Most infants will start sleeping through the ... may take a little longer, however, is for the baby,s ... schedule, according to the study. "The most rapid changes ...
... PICK: Pregnancy outcome affected by immune system genes ... Moffett, at the University of Cambridge, United Kingdom, has ... to and provide protection from common disorders of pregnancy, ... A key step in the initiation of a successful ...
Cached Medicine News:Health News:Aspirin May Help Patients Beat Prostate Cancer 2Health News:Aspirin May Help Patients Beat Prostate Cancer 3Health News:Highly targeted radiation technique minimizes side effects of prostate cancer treatment 2Health News:Chemotherapy plus radiation prevents bladder cancer recurrences 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 3Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 3Health News:JCI table of contents: Oct. 25, 2010 2Health News:JCI table of contents: Oct. 25, 2010 3Health News:JCI table of contents: Oct. 25, 2010 4Health News:JCI table of contents: Oct. 25, 2010 5Health News:JCI table of contents: Oct. 25, 2010 6Health News:JCI table of contents: Oct. 25, 2010 7Health News:JCI table of contents: Oct. 25, 2010 8Health News:JCI table of contents: Oct. 25, 2010 9
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: